Novo And Lilly Lay Out Patient Segmentation Plans For Obesity Treatment

 
• By Andrew McConaghie
  
Novo's Wegovy and Ozempic are under increasing pressure from Lilly's rival products, and both companies aim to tailor therapies to different patient group needs.

More from Strategy

More from Therapy Areas